Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: The invention relates to an ORC (Organic Rankine Cycle) for the conversion of thermal energy into electric energy, comprising at least one heat exchanger unit for re-superheating the working fluid by means of the thermovector fluid from the hot source, between the discharge of the first expander and the input of the second expander, and a regenerator unit including a first regenerator and at least one second regenerator for regenerating the working fluid in at least two successive stages, in said first regenerator and at least in said second regenerator respectively, with an additional regenerative heat exchange along the flow line connecting the liquid working fluid output of the second regenerator to the liquid working fluid input of the first regenerator.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.

Abstract: The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof.

Abstract: The present invention relates to the use of 2-indanylamino derivatives for the treatment of chronic pain. In particular the invention relates to the use of 2-(2-indanylamino)-acetamide for the treatment of neuropathic pain, i.e. the pain associated with postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy and nerve distruction by the human immunodeficiency virus (HIV).

Abstract: A process for the preparation of compounds of formula (I), wherein R is C2-C20 linear or branched alkyl, C3-C7 cycloalkyl, phenyl or benzyl, which can optionally be substituted by C1-C4 alkyl, halogen or C1-C4 alkoxy group, said process comprising: a) oxidation of eserine with hydrogen peroxide in the presence of a base and subsequent hydrolysis to geneseroline, without isolating the intermediate geneserine; b) acylation of geneseroline with an isocyanate of formula R—N═C═O, wherein R is as defined above, in the presence of a basic catalyst; c) optional transformation into a pharmaceutically acceptable salt. Compounds of formula (I) wherein R is a phenyl or benzyl, which can be optionally substituted by alkyl, halogen or alkoxy, are selective, potent brain anticholinesterase inhibitors.

Abstract: The present invention relates to serinamide, glycinamide, alaninamide and phenylalaninamide derivatives of formula (I) wherein R, R', R.sub.1 and R.sub.2 are as defined in the disclosure. The compounds (I) are useful for the treatment of neurological diseases.